Mark T. Miedel

University of Pittsburgh

Papers

1

Total Citations

176

H-Index

1

About

Mark T. Miedel is a leading figure in the development of advanced in vitro models for toxicology, with a primary focus on microphysiological systems and organ-on-a-chip technology. His most impactful contribution is the creation and validation of the OrganoPlate LiverTox™, a groundbreaking 3D microfluidic liver model for high-throughput compound toxicity screening. This work, detailed in his highly cited 2021 paper (176 citations), demonstrates the successful integration of induced pluripotent stem cell (iPSC)-derived hepatocytes into a perfused, multi-well platform, enabling automated and scalable hepatotoxicity testing. By bridging the gap between traditional 2D cultures and costly animal models, Miedel’s research provides a more physiologically relevant tool for predicting drug-induced liver injury. His achievements have significantly advanced the field of predictive toxicology, offering pharmaceutical researchers a robust, human-relevant platform for early-stage safety assessment. Miedel’s work stands as a cornerstone in the push toward more ethical, efficient, and accurate preclinical drug development.

Research Focus

Key Achievements

1
H-Index
1
Papers
176
Total Citations
176
Avg Citations/Paper
🏆 Most Cited Paper
A 3D microfluidic liver model for high throughput compound toxicity screening in the OrganoPlate®
176 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 8
🏛 Institutions: University of Pittsburgh

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago